Blood Cancer Journal

Welcome to Blood Cancer Journal

A peer-reviewed fully open access journal dedicated to publishing articles of the highest quality related to hematologic malignancies and related disorders

Featured

Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group

Guadalupe Oñate
Ana Garrido
Jorge Sierra
ArticleOpen Access11 Jan 2025
A MYC-rearrangement is a negative prognostic factor in stage II, but not in stage I diffuse large B-cell lymphoma

A. V. de Jonge
J. A. A. Bult
M. Brink
ArticleOpen Access04 Jan 2024
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy

Maximilian Merz
Danai Dima
Nico Gagelmann
ArticleOpen Access05 Dec 2024
CAR-T cell therapy in Multiple Myeloma: current status and future challenges

Dawn Swan
Deepu Madduri
Jay Hocking
Review ArticleOpen Access26 Nov 2024

Announcements

COLLECTION: Current Treatment Algorithms

Blood Cancer Journal proudly publishes ‘Current Treatment Algorithms’, an article type dedicated to providing clear, authoritative, concise treatment pathways for hematologic malignancies. Read the full series here.
Featured article including author video summary

Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM) Listen to the authors of this article discussing their recommendations for the assessment and management of belamaf-associated ocular events to help mitigate ocular risk and enable patients to continue to experience a clinical benefit with belamaf.
Get your manuscript ready for journal editors

Follow our checklist to avoid common mistakes to help get your manuscript to journal editors faster. We also offer a FREE language check from our partner AJE.
Follow us on Twitter!

Join the Blood Cancer Journal Twitter Community
@BloodCancerJnl
Follow us to keep up-to-date with the latest research and news from Blood Cancer Journal. Share your views, retweet and give us feedback.

Browse articles

Different definitions in intention-to-treat analysis for chimeric antigen receptor T-cell therapy depend on research scope

Lisa Argnani
Beatrice Casadei
Pier Luigi Zinzani
CorrespondenceOpen Access07 Mar 2025
Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma

James A. Davis
Jordan Snyder
Victoria R. Nachar
CorrespondenceOpen Access04 Mar 2025
Evolution of WHO diagnostic criteria in “Classical Myeloproliferative Neoplasms” compared with the International Consensus Classification

Jürgen Thiele
Hans Michael Kvasnicka
Attilio Orazi
Review ArticleOpen Access04 Mar 2025
Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK National CAR T Panel

Vaishali Dulobdas
Amy A. Kirkwood
Sridhar Chaganti
ArticleOpen Access04 Mar 2025
Myeloid neoplasms with MYC-positive double minutes: towards recognition as a distinct entity

Isolde Summerer
Wencke Walter
Christian Pohlkamp
CorrespondenceOpen Access03 Mar 2025
Impact of baseline genetic profile and treatment on outcome and hematological toxicity in CEBPA-mutated AML

Francesco Mannelli
Matteo Piccini
Alessandro M. Vannucchi
CorrespondenceOpen Access01 Mar 2025
Myeloid neoplasms with PHF6 mutations: context-dependent genomic and prognostic characterization in 176 informative cases

Saubia Fathima
Ali Alsugair
Ayalew Tefferi
ArticleOpen Access01 Mar 2025
Multiple myeloma as a challenging multidimensional random process: a data-driven web-based application for treatment selection

Alexander S. Luchinin
Tigran G. Gevorkyan
Anastasia A. Semenova
EditorialOpen Access27 Feb 2025
Targeting osteoclasts for treatment of high-risk B-cell acute lymphoblastic leukemia

Rishi S. Kotecha
Sarah M. Trinder
Laurence C. Cheung
CorrespondenceOpen Access27 Feb 2025

A new year brings a new series for Blood Cancer Journal - January 2018 sees the launch of a new article type called ‘Current Treatment Algorithms’, a new series dedicated to providing clear, authoritative, concise treatment pathways for hematologic malignancies.

Collection 12 Jan 2018

Trending - Altmetric

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics.

Welcome to Blood Cancer Journal

Featured

Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group

A MYC-rearrangement is a negative prognostic factor in stage II, but not in stage I diffuse large B-cell lymphoma

Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy

CAR-T cell therapy in Multiple Myeloma: current status and future challenges

Announcements

COLLECTION: Current Treatment Algorithms

Featured article including author video summary

Get your manuscript ready for journal editors

Follow us on Twitter!

Browse articles

Different definitions in intention-to-treat analysis for chimeric antigen receptor T-cell therapy depend on research scope

Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma

Evolution of WHO diagnostic criteria in “Classical Myeloproliferative Neoplasms” compared with the International Consensus Classification

Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK National CAR T Panel

Myeloid neoplasms with MYC-positive double minutes: towards recognition as a distinct entity

Impact of baseline genetic profile and treatment on outcome and hematological toxicity in CEBPA-mutated AML

Myeloid neoplasms with PHF6 mutations: context-dependent genomic and prognostic characterization in 176 informative cases

Multiple myeloma as a challenging multidimensional random process: a data-driven web-based application for treatment selection

Targeting osteoclasts for treatment of high-risk B-cell acute lymphoblastic leukemia

Collections

Current Treatment Algorithms

Trending - Altmetric

Search

Quick links

Featured

Announcements

Advertisement

Trending - Altmetric

Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study

Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma

Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases

Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK National CAR T Panel

Search

Quick links